194 related articles for article (PubMed ID: 16598051)
21. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
Forciniti S
Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
[No Abstract] [Full Text] [Related]
22. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
[TBL] [Abstract][Full Text] [Related]
23. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
24. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
25. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
Gori S; Anastasi P; Marrocolo F
Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
[No Abstract] [Full Text] [Related]
26. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
27. Anastrozole.
Cuzick J
Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
[TBL] [Abstract][Full Text] [Related]
28. Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Altundag K; Dede D; Harputluoglu H; Gullu I
Joint Bone Spine; 2007 Dec; 74(6):662-3. PubMed ID: 17913550
[No Abstract] [Full Text] [Related]
29. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Le Rhun E; Delbeuck X; Lefeuvre-Plesse C; Kramar A; Skrobala E; Pasquier F; Bonneterre J
Breast Cancer Res Treat; 2015 Aug; 152(3):569-80. PubMed ID: 26160250
[TBL] [Abstract][Full Text] [Related]
30. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Mouridsen H; Keshaviah A; Coates AS; Rabaglio M; Castiglione-Gertsch M; Sun Z; Thürlimann B; Mauriac L; Forbes JF; Paridaens R; Gelber RD; Colleoni M; Smith I; Price KN; Goldhirsch A
J Clin Oncol; 2007 Dec; 25(36):5715-22. PubMed ID: 17998546
[TBL] [Abstract][Full Text] [Related]
32. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
33. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
[TBL] [Abstract][Full Text] [Related]
34. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
35. Overcoming recurrence risk: extended adjuvant endocrine therapy.
Cianfrocca M
Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
[TBL] [Abstract][Full Text] [Related]
36. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
37. World's largest breast cancer treatment trial supports anastrozole use.
Oncology (Williston Park); 2002 Jan; 16(1):63. PubMed ID: 11831610
[No Abstract] [Full Text] [Related]
38. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
39. Bone density in breast cancer: when to intervene?
Gralow JR
J Clin Oncol; 2007 Aug; 25(22):3194-7. PubMed ID: 17577014
[No Abstract] [Full Text] [Related]
40. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
